

CURRICULUM VITAE ET STUDIORUM, MASSIMILIANO AGOSTINI

2014-present. Associate Professor, Molecular Biology, University of Rome “Tor Vergata”, Italy.
Dept. Experimental Medicine and Surgery University of Rome “Tor Vergata” via Montpellier, 1
00133 Roma, Italy

2019-present Consiglio Tecnico Scientifico del Centro interdipartimentale per la medicina comparata, l’acqua coltura e le tecniche alternative (CIMETA, University of Rome “Tor Vergata”)

Public record <http://orcid.org/0000-0003-3124-2072>

Researcher ID: G-9579-2014 <http://www.researcherid.com/rid/G-9579-2014>

Massimiliano Agostini is Associate Professor in Molecular Biology at the University of Rome “Tor Vergata”. He obtained his PhD in Clinical and Experimental Pharmacology (Perugia, Italy), working on the pharmacological regulation of the immune response. In 2005, he became a Research Assistant at University of Perugia (Italy). In 2007-2014, he worked at the MRC Toxicology Unit, (UK), as PostDoc and then as Senior Investigator. In 2014 worked at TW Mak’s laboratory as visiting scientist (Canada). From 2014 to 2019 Visiting Scientist, MRC Toxicology Unit, Cambridge University, UK. He is mainly interested in the characterization of transgenic mice with genetic alterations in the p53 family genes and their targets to understand their effect on development and cancer. In particular, he aims to investigate the role of the transcription factor ZNF750 (transcriptionally regulated by p63) in tumorigenesis by using combining *in vitro* and *in vivo* models combined with system biology (transcriptomics, proteomics and metabolomics).

EDUCATION

1991-1997 Chemical and Pharmaceutical Technology, University of Perugia, Italy

1997 **Degree in** Chemical and Pharmaceutical Technology

1998 Pharmacist license, state of Italy

2001-2005 (23 January 2006) **PhD Studies** in Clinical and Experimental Pharmacology: Dept. Clinical and Experimental Medicine, Section of Pharmacology, University of Perugia, Italy.
Title PhD Thesis: Pro-inflammatory role of GITR (Glucocorticoid-Induced TNFR related family) in animal models of autoimmune diseases

CAREER HISTORY

1997-1999: Visiting Fellow Section of Pharmacology, School of Medicine, University of Perugia, Italy

1999-2001: Fellowship Section of Pharmacology, School of Medicine, University of Perugia, Italy

15/11/05-14/11/06 Research Assistant Section of Pharmacology, School of Medicine, University of Perugia, Italy

15/11/06-14/11/07 Research Assistant Section of Pharmacology, School of Medicine, University of Perugia, Italy

15 July 2007-July 2011 Career Development Fellow, MRC Toxicology Unit

26 April 2014- 16 June 2014 Visiting Scientist, at The Campbell Family Institute for Breast Cancer Research, Tak W. Mak laboratory, Toronto, Canada

July 2011-December 2014 Senior Investigator, MRC Toxicology Unit

2014 to 2019 Visiting Scientist, MRC Toxicology Unit, Cambridge University, UK.

EDUCATIONAL ACTIVITIES

Tutoring activity: guidance of compilative and experimental thesis of student of School of Medicine, Chemistry and Pharmaceutical Technology, Pharmacy and Biological Sciences

- 2001-2003** Exam Committees for Pharmacology, course for Odontology, Dental Prosthetics, University of Perugia, Italy
- 2002-2007** Exam Committees for Pharmacology, School of Medicine, University of Perugia, Italy
- 2012-present** Faculty Board PhD Biochemistry and Molecular Biology, Dept. Experimental Medicine and Surgery, University of Rome Tor Vergata

Teaching Activities

- 2015-Present** II level Master, Personalized Nutrition: Molecular and Genetic bases, University of Rome Tor Vergata, Italy 1CFU
- 2016-Present** I level Master, Nutrition and Cosmesis, University of Rome Tor Vergata, Italy 2CFU
- 2016-2020** International Medical School (Biochemistry 4CFU) and Molecular Biology 2CFU) University of Rome Tor Vergata, Italy
- 2016-Present** International Medical School (Molecular Biology 3CFU) University of Rome Tor Vergata, Italy
- 2017-Present** Specialization School of Infection Disease University of Rome Tor Vergata, Italy (Molecular Biology 1CFU)
- 2018 -2019** School of Medicine and Surgery (Molecular Biology 1CFU) University of Rome Tor Vergata, Italy
- 2019-Present** Specialization School of Microbiology and Virology University of Rome Tor Vergata, Italy (Molecular Biology 2CFU)
- 2020-Present** International Medical School (Molecular Biology 3CFU) University of Rome Tor Vergata, Italy
- 2020-Present** Course of Pharmacy (Biochemistry 6CFU) University of Rome Tor Vergata, Italy
- 2021-Present** Scienze della nutrizione umana (Principi di metabolomica 2CFU)

Tutoring Activities

- 2018** Master Degree Thesis in Molecular Biology, Candidate Francesco Rugolo
- 2018** Master Degree Thesis in Molecular Biology, Candidate Elisabetta Cerasaro
- 2020** Master Degree Thesis in Medical Biotechnology, Candidate Stefano D'Anna
- 2021** Master Degree Thesis in Cellular and Molecular Biology, Candidate Giorgio Tremolizzo
- 2022** Bachelor and Master's Degree Thesis in Pharmacy, Candidate Loveth Obidike
- 2014-2017** PhD in Biochemistry and Molecular Biology, Candidate Dr Matteo Cassandri
- 2017- 2020** PhD in Biochemistry and Molecular Biology, Candidate Dr Alessio Buterra
- 2018-2021** PhD in Biochemistry and Molecular Biology, Candidate Dr Francesco Rugolo

- 2016** II level Master, Personalized Nutrition: Molecular and Genetic bases, University of Rome Tor Vergata, "Il ruolo delle proteine nelle malattie infiammatorie e oncologiche" Candidate Dr Davide Sparpaglia
- 2019** II level Master, Personalized Nutrition: Molecular and Genetic bases, University of Rome Tor Vergata, Candidate Dr Giulia Pesce
- 2020** II level Master, Personalized Nutrition: Molecular and Genetic bases, University of Rome Tor Vergata, Candidate Dr Rinaldo Migliaccio
- 2020** I level Master, Nutrition and Cosmesis, University of Rome Tor Vergata, Dr Giulia La Torre

Thesis committee

- II level Master, Personalized Nutrition: Molecular and Genetic bases, University of Rome Tor Vergata, Italy
- I level Master, Nutrition and Cosmesis, University of Rome Tor Vergata, Italy

PhD committee

February 2017 XXIX cycle PhD programme in Life Science University of Rome, La Sapienza, Italy.

February 2018 XXX cycle PhD programme in Life Science University of Rome, La Sapienza, Italy.

January 2019 XXX cycle PhD programme in Biochemistry and Molecular Biology, University of Rome Tor Vergata, Italy

April 2019 XXXI cycle PhD programme in Biotechnology, University of Perugia, Italy

February 2020 XXXII cycle PhD programme in Biotechnology, University of Perugia, Italy

March 2020 XXXII cycle PhD programme in Bioengineering and Medical-Surgical Sciences

External reviewer for PhD thesis

2014 October, PhD in Biochemistry and Molecular Biology, at University of Rome “Tor Vergata”
“Impact of non-coding RNAs on skin homeostasis” by Mara Mancini

2016 March, PhD Program N094, at the Medical University of Vienna, “Effect of chemotherapy on anti tumor immune response” by Liang Ying Yu

2017 January, PhD in Biotechnology, University of Perugia, Italy “GILZ è una proteina fondamentale nella funzionalità dei neutrofili” by Erika Ricci

2017 November PhD in Biotechnology, University of Perugia, Italy “GITR, un marker cruciale delle cellule T regolatorie: implicazioni terapeutiche” by Luigi Cari

2020 January 2020 XXXII cycle PhD programme in Bioengineering and Medical-Surgical Sciences “Development of innovative biomimetic scaffolds for improving recovery of erectile function after radical prostatectomy” by Riccardo Giuseppe Bertolo

EDITORIAL EXPERIENCE

2014-2019 Editorial board of *Molecular & Cellular Oncology*

Receiving Editor *Cell Death & Disease*

Editorial board as Review Editor of *Frontiers in Cancer Molecular Targets and Therapeutics*

Ad hoc Referee:

Cell Death & Disease, Cell Death and Differentiation, Frontiers in Cancer, Molecular and Cellular Oncology, Molecular Neurobiology, Oncogene, Oncotarget, Cell Cycle, FEBS Journal, Scientific Reports, Journal of Cellular Biochemistry, Molecular Oncology, FASEB Journal, Journal of Human Genetics, Biology Direct, Discover Oncology

PUBLICATION

Scientific Papers	73 (First Author: 17; Corresponding Author: 10)		
Citations	4977 (Scholar)	3448 (ISI)	3646 (Scopus)
h-Index	41 (Scholar)	36 (ISI)	37 (Scopus)

15 Most representative papers

1. Rugolo F, et al The expression of ELOVL4, repressed by MYCN, defines neuroblastoma patients with good outcome *Oncogene* 2021 Sep;40(38):5741-5751 [**IF 9.86**]
2. Velletri T, et al Loss of p53 in mesenchymal stem cells promotes alteration of bone remodelling through negative regulation of osteoprotegerin *Cell Death Differ* 2021 Jan;28(1):156-169. [**IF 15.82**]
3. Cassandri M et al. **Agostini M** and Melino G ZNF750 represses breast cancer invasion via epigenetic control of prometastatic genes *Oncogene* **39**, 4331–4343 (2020). [**IF 7.97**]
4. Pieraccioli M, Nicolai S, Pitolli C, **Agostini M**, et al. ZNF281 inhibits neuronal differentiation and is a prognostic marker for neuroblastoma *PNAS U S A* 2018; 115(28):7356-7361. [**IF 9.55**]
5. **Agostini M**, et al p73 regulates primary cortical neurons metabolism: a global metabolic profile *Mol Neurobiol.* 2017 2017 May 6. doi: 10.1007/s12035-017-0517-3. [**IF 5.39**]

6. **Agostini M**, et al Metabolic reprogramming during neuronal differentiation *Cell Death Differ* 2016 Sep 1;23(9):1502-14. [**IF 8.18**]
7. Viticchiè G, et al Δ Np63 supports aerobic respiration through hexokinase II *Proc Natl Acad Sci USA*. 2015 Sep 15;112(37):11577-82. [**IF 9.67**]
8. Amelio I, et al. Serine and glycine metabolism in Cancer *Trends Biochem Sci* 2014 Apr;39(4):191-198. [**IF 11.23**]
9. Inoue S, et al. TAp73 is required for spermatogenesis and the maintenance of male fertility. *Proc Natl Acad Sci USA*. 2014 Feb 4;111(5):1843-8. [**IF 9.67**]
10. Niklison-Chirou MV, et al. TAp73 knockout mice show morphological and functional nervous system defects associated with loss of p75NTR *Proc Natl Acad Sci U S A* 2013 Nov 19;110(47):18952-7. [**IF 9.67**]
11. Tucci P*, **Agostini M***, et al. Loss of p63 and its miR-205 target results in enhanced cell migration and metastasis in prostate cancer. *Proc Natl Acad Sci U S A*. 2012 Sep 18;109(38):15312-7. (*) Co-First Author [**IF 9.67**]
12. He Z, et al. p73 regulates autophagy and hepatocellular lipid metabolism through a transcriptional activation of the ATG5 gene. *Cell Death Differ*. 2013 Oct;20(10):1415-24. [**IF 8.18**]
13. Amelio I, et al. p73 regulates serine biosynthesis in cancer. *Oncogene*. 2013 Nov 4. doi: 10.1038/onc.2013.456. [**IF 8.46**]
14. **Agostini M**, et al. miR-34a regulates neurite outgrowth, spinal morphology and function. *Proc Natl Acad Sci U S A*. 2011 Dec 27;108(52):21099-104. [**IF 9.67**]
15. **Agostini M**, et al. Neuronal differentiation by TAp73 is mediated by miR-34a regulation of synaptic protein targets. *Proc Natl Acad Sci U S A*. 2011 Dec 27;108(52):21093-8. [**IF 9.67**]